Choose a procedure, then see what has cohort evidence, what appears only in structured community reports, and what is recognised but missing from the current dataset.
These groups describe the coverage of this database—not a ranking of severity or a personal risk estimate.
Source-linked study data. Each number stays attached to its cohort, denominator and follow-up period.
Severe infection or inflammation inside the eye after intraocular surgery. It is distinct from a surface corneal infection.
FDA recognition source ↗Scattered or uncomfortable brightness, ghosting or poorer visual quality in low light. Definitions and questionnaires vary.
FDA recognition source ↗Rings around lights, especially under dim or night-time conditions. Studies may use different questions and symptom thresholds.
FDA recognition source ↗Clouding behind the implanted lens after lens extraction, sometimes treated with a laser capsulotomy. A capsulotomy rate is not identical to an opacification rate.
FDA recognition source ↗Separation or tearing of the retina requiring urgent assessment and sometimes surgery. Baseline retinal risk and procedure context matter.
FDA recognition source ↗Rays or streaks around point light sources, usually assessed through a patient questionnaire rather than a single universal test.
FDA recognition source ↗An anecdotal layer kept separate from clinical evidence; these counts are not incidence estimates.
Under-correction, over-correction, regression or another refractive result that may leave a need for glasses, contact lenses or an additional procedure.
FDA recognition source ↗1 approved public-forum report contains an issue-specific structured mention. This is not an incidence estimate.
Browse RLE community reports →Coverage gaps remain visible because missing data must not be mistaken for zero events.
Loss of the cells that keep the cornea clear; substantial loss can contribute to persistent corneal swelling and reduced vision.
FDA recognition source ↗Postoperative swelling in the central retina that can reduce or distort vision.
FDA recognition source ↗Movement of the implanted replacement lens away from its intended position, potentially requiring repositioning or exchange.
FDA recognition source ↗A reduction in chart lines even with the best glasses or contact-lens correction available after surgery.
FDA recognition source ↗Inflammation inside the eye after an intraocular procedure, assessed separately from infection.
FDA recognition source ↗An increase in pressure inside the eye, including early postoperative pressure rise or longer-term pressure-related damage requiring monitoring or treatment.
FDA recognition source ↗